PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 2% – Here’s What Happened

PharmaCyte Biotech Inc (OTCMKTS:PMCBD)’s stock price was down 2% during trading on Friday. The stock traded as low as $0.34 and last traded at $0.3431. 69,450 shares changed hands during mid-day trading, an increase of 686% from the average session volume of 8,831 shares. The stock had previously closed at $0.3501.

PharmaCyte Biotech Stock Performance

The stock has a 50-day moving average of $0.43 and a 200 day moving average of $0.65.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc is a clinical-stage biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s primary program has centered on locally advanced pancreatic cancer, an aggressive disease with limited treatment options.

PharmaCyte’s investigational approach uses its Cell-in-a-Box technology, which involves encapsulating genetically engineered cells in proprietary cellulose-based capsules. These cells are designed to produce an enzyme that converts the chemotherapy prodrug ifosfamide into its active form near the tumor, with the goal of concentrating treatment at the disease site while reducing exposure to healthy tissue.

PharmaCyte Biotech does not have commercially marketed products and has focused primarily on research, clinical development, regulatory activities and potential partnerships.